ALINARI, LAPO
 Distribuzione geografica
Continente #
NA - Nord America 1.590
EU - Europa 1.177
AS - Asia 461
AF - Africa 88
Continente sconosciuto - Info sul continente non disponibili 1
OC - Oceania 1
SA - Sud America 1
Totale 3.319
Nazione #
US - Stati Uniti d'America 1.581
GB - Regno Unito 361
SE - Svezia 251
CN - Cina 144
DE - Germania 132
VN - Vietnam 130
IT - Italia 123
UA - Ucraina 84
SG - Singapore 76
IN - India 51
IE - Irlanda 48
RU - Federazione Russa 42
FR - Francia 36
HR - Croazia 30
JO - Giordania 26
CI - Costa d'Avorio 24
ZA - Sudafrica 24
TG - Togo 21
CH - Svizzera 19
EE - Estonia 17
BE - Belgio 11
JP - Giappone 11
IR - Iran 10
NG - Nigeria 10
BG - Bulgaria 7
CA - Canada 6
ES - Italia 5
SC - Seychelles 5
TN - Tunisia 4
FI - Finlandia 3
GR - Grecia 3
MX - Messico 3
TR - Turchia 3
TW - Taiwan 3
LB - Libano 2
A2 - ???statistics.table.value.countryCode.A2??? 1
CL - Cile 1
CZ - Repubblica Ceca 1
DK - Danimarca 1
HK - Hong Kong 1
ID - Indonesia 1
IQ - Iraq 1
MY - Malesia 1
NO - Norvegia 1
NZ - Nuova Zelanda 1
PL - Polonia 1
RO - Romania 1
UZ - Uzbekistan 1
Totale 3.319
Città #
Southend 316
Chandler 178
Fairfield 175
Ann Arbor 155
Ashburn 105
Woodbridge 104
Seattle 99
Houston 96
Wilmington 87
Cambridge 80
Jacksonville 60
Singapore 60
Princeton 56
Dublin 48
Dong Ket 33
Nanjing 33
Padova 27
Turin 27
Westminster 27
Amman 26
Abidjan 24
New York 23
Lomé 21
Berlin 20
Beijing 19
Saint Petersburg 15
Bern 14
Boardman 14
Los Angeles 14
Jinan 13
Bologna 12
Redwood City 12
Santa Clara 12
Shenyang 12
Brussels 11
Nanchang 11
Abeokuta 10
Florence 10
Tokyo 10
Bremen 9
Milan 9
Mülheim 9
San Diego 9
Jiaxing 8
Changsha 7
Sofia 7
Zhengzhou 7
Hebei 6
Zanjan 6
Dearborn 5
Ningbo 5
Norwalk 5
Kunming 4
Lausanne 4
Mahé 4
Tianjin 4
Falls Church 3
Gallarate 3
Helsinki 3
Istanbul 3
London 3
Madrid 3
Mexico 3
Taipei City 3
Taizhou 3
Verona 3
Winnipeg 3
Andover 2
Barcelona 2
Buffalo 2
Fremont 2
Haikou 2
Hangzhou 2
Leawood 2
Monmouth Junction 2
Olalla 2
Sacramento 2
Taiyuan 2
Wayne 2
Auckland 1
Baghdad 1
Brindisi 1
Büdelsdorf 1
Carol Stream 1
Chicago 1
Cupertino 1
Des Moines 1
Edmonton 1
Falkenstein 1
Frankfurt Am Main 1
Genzano Di Roma 1
Guangzhou 1
Hanover 1
Hefei 1
Henderson 1
Hope 1
Hyderabad 1
Jakarta 1
Kitchener 1
Medford 1
Totale 2.255
Nome #
18F-FDG PET early after radiotherapy in lymphoma patients. 231
A phase II trial of CHOP chemotherapy followed by yttrium 90 ibritumomab tiuxetan (Zevalin) for previously untreated elderly diffuse large B-cell lymphoma patients. 172
Predictive role of positron emission tomography (PET) in the outcome of lymphoma patients. 169
18 F-FDG PET in malignant lymphoma: significance of positive findings 161
18F-FDG PET in mucosa-associated lymphoid tissue (MALT) lymphoma. 160
Histological verification of positive positron emission tomography findings in the follow-up of patients with mediastinal lymphoma. 138
High-dose therapy with autologous transplantation for aggressive non-Hodgkin's lymphoma: the Bologna experience 138
Fludarabine plus mitoxantrone with and without rituximab versus CHOP with and without rituximab as front-line treatment for patients with follicular lymphoma. 129
Phase II study of a single pegfilgrastim injection as an adjunct to chemotherapy to mobilize stem cells into the peripheral blood of pretreated lymphoma patients. 127
Role of [18F]Fluorodeoxyglucose Positron Emission Tomography Scan in the Follow-Up of Lymphoma 127
Potential pitfalls of 18F-FDG PET in a large series of patients treated for malignant lymphoma: prevalence and scan interpretation. 123
Efficacy and safety of oral fludarabine/cyclophosphamide regimen in previously treated indolent lymphomas. 119
Effectiveness of Fludarabine, Idarubicin and Cyclophosphade (FLUIC) Combination Regimen for Young Patients with Untreated Non-Follicular Low-Grade Non-Hodgkin’s Lymphoma. 117
Role of anemia in survival of patients with elderly aggressive non-Hodgkin's lymphoma after chemotherapy. 117
Gemcitabine as frontline treatment for cutaneous T-cell lymphoma. 117
Phase II trial of temozolomide in patients with pretreated cutaneous T-cell lymphoma. 115
Identification of outcome predictors in diffuse large B-cell lymphoma. Immunohistochemical profiling of homogeneously treated de novo tumors with nodal presentation on tissue micro-arrays. 113
Early positron emission tomography (PET) restaging: a predictive final response in Hodgkin's disease patients. 110
Preliminary observations of a phase II study of reduced-dose alemtuzumab treatment in patients with pretreated T-cell lymphoma. 109
Discordant response to chemotherapy: An unusual patternof fluoro-deoxy-d-glucose uptake in heavily pre-treated lymphoma patients. 108
Pretransplantation positron emission tomography scan is the main predictor of autologous stem cell transplantation outcome in aggressive B-cell non-Hodgkin lymphoma. 108
Value of oxaliplatin treatment in heavily pretreated patients with non-Hodgkin's lymphoma. 106
Fludarabine-containing chemotherapy as frontline treatment of nongastrointestinal mucosa-associated lymphoid tissue lymphoma. 103
Rituximab in primary conjunctiva lymphoma. 89
Prognostic factors in primary cutaneous B-cell lymphoma: the Italian Study Group for Cutaneous Lymphomas. 89
Long-term follow-up of front-line treatment of hairy cell leukemia with 2-chlorodeoxyadenosine 83
FDG-PET in the serial assessment of patinets with lymphoma in complete remission 81
Erratum: Phase II study of a single pegfilgrastim injection as an adjunct to chemotherapy to mobilize stem cells into the peripheral blood of pretreated lymphoma patients (Haematologica (2005) 90, (225-231). 23
Totale 3.382
Categoria #
all - tutte 8.000
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 8.000


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020732 0 0 11 60 91 90 106 125 112 53 40 44
2020/2021486 93 32 8 22 17 90 12 37 33 30 37 75
2021/2022717 156 16 56 97 42 28 14 41 15 39 139 74
2022/2023736 84 88 46 87 57 59 12 32 157 21 58 35
2023/2024150 7 32 9 20 12 41 6 5 3 10 3 2
2024/2025124 10 112 2 0 0 0 0 0 0 0 0 0
Totale 3.382